This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SALT LAKE CITY, Jan. 28, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has published details of its myVision™ Myriad Variant Classification Program in the journal
Clinical Genetics. myVision is the most advanced variant classification program available to determine whether a patient's genetic variant (mutation) is benign or deleterious. myVision employs a number of robust scientific methods and is backed by Myriad's 20 years of clinical research and testing in more than one million patients.
"Patients who receive a genetic test that identifies a variant of uncertain significance (VUS) do not know if their mutation is benign or deleterious and associated with hereditary cancer risk. This lack of clarity is emotionally difficult and confusing for patients who are making medical decisions and may translate into substantial downstream healthcare costs," said Richard Wenstrup, M.D., chief medical officer at Myriad Genetics Laboratories. "Myriad has been a leader in the field of variant classification and has significantly reduced the VUS rate for patients of all ethnic groups."
Since 2002, Myriad's variant classification program has significantly lowered the VUS rate for all major ethnic groups by approximately tenfold. For example, among patients of African ancestry, the VUS rate was reduced from 38.6 percent to 3.6 percent and for patients with Latin ancestry, the VUS rate was lowered from 26.1 percent to 3 percent.
These unparalleled results are attributable to Myriad's investment in two proprietary statistical classification tools including Pheno™ and MCo™, which were developed using a validation set of more than 400,000 patients. These tools provide classification accuracy of greater than 99 percent, whereas some of the statistical methods used by others, such as Sift Poly Phen, have classification accuracies as low as 57 percent.
Myriad has a lifetime commitment to provide the most up-to-date and accurate variant information to patients and their families. For example, the Company offers genetic testing at no cost to selected family members in order to clarify VUS results and reinforce previous findings. Myriad also continually evaluates new information as it emerges to classify VUS quickly and accurately. If a VUS is classified in the future, the Company sends this critical information to patients' healthcare providers at no additional cost to the patient.